

Enhanced Ryanodine Receptor-Mediated Calcium Leak Determines Reduced Sarcoplasmic Reticulum Calcium Content in Chronic Canine Heart Failure

Andriy Belevych,^{*†} Zuzana Kubalova,[¶] Dmitry Terentyev,^{*†} Robert L. Hamlin,[‡] Cynthia A. Carnes,^{*§} and Sandor Györke^{*†}

^{*}Davis Heart and Lung Research Institute, [†]Department of Physiology and Cell Biology, [‡]Department of Veterinary Biosciences, and [§]College of Pharmacy, The Ohio State University Medical Center, Columbus, Ohio 43210; and [¶]Institute of Molecular Physiology and Genetics, Slovak Academy of Sciences, Bratislava, Slovak Republic

ABSTRACT In this study, we investigated the role of elevated sarcoplasmic reticulum (SR) Ca^{2+} leak through ryanodine receptors (RyR2s) in heart failure (HF)-related abnormalities of intracellular Ca^{2+} handling, using a canine model of chronic HF. The cytosolic Ca^{2+} transients were reduced in amplitude and slowed in duration in HF myocytes compared with control, changes paralleled by a dramatic reduction in the total SR Ca^{2+} content. Direct measurements of $[\text{Ca}^{2+}]_{\text{SR}}$ in both intact and permeabilized cardiac myocytes demonstrated that SR luminal $[\text{Ca}^{2+}]$ is markedly lowered in HF, suggesting that alterations in Ca^{2+} transport rather than fractional SR volume reduction accounts for the diminished Ca^{2+} release capacity of SR in HF. SR Ca^{2+} ATPase (SERCA2)-mediated SR Ca^{2+} uptake rate was not significantly altered, and $\text{Na}^+/\text{Ca}^{2+}$ exchange activity was accelerated in HF myocytes. At the same time, SR Ca^{2+} leak, measured directly as a loss of $[\text{Ca}^{2+}]_{\text{SR}}$ after inhibition of SERCA2 by thapsigargin, was markedly enhanced in HF myocytes. Moreover, the reduced $[\text{Ca}^{2+}]_{\text{SR}}$ in HF myocytes could be nearly completely restored by the RyR2 channel blocker ruthenium red. The effects of HF on cytosolic and SR luminal Ca^{2+} signals could be reasonably well mimicked by the RyR2 channel agonist caffeine. Taken together, these results suggest that RyR2-mediated SR Ca^{2+} leak is a major factor in the abnormal intracellular Ca^{2+} handling that critically contributes to the reduced SR Ca^{2+} content of failing cardiomyocytes.

INTRODUCTION

In cardiac muscle, contraction and relaxation are controlled by the sarcoplasmic reticulum (SR), a Ca^{2+} storage and release organelle equipped with specialized molecules to pump Ca^{2+} into and release Ca^{2+} out of the SR lumen, namely the SR Ca^{2+} ATPase (SERCA2) and the ryanodine receptor (RyR2) channel, respectively (1). Contraction is triggered when a small amount of Ca^{2+} enters the myocyte via voltage-dependent Ca^{2+} channels and is amplified by Ca^{2+} -induced Ca^{2+} release (CICR) (2) from the SR through RyR2s, causing activation of the myofilaments. After CICR, Ca^{2+} release robustly terminates and enters a refractory state, processes that are governed by the decline in intra-SR $[\text{Ca}^{2+}]$ that accompanies SR Ca^{2+} release (3–5). Once the RyR2 channels close, Ca^{2+} can be effectively pumped back to the SR by SERCA2, contributing to cardiac relaxation. Although most of the Ca^{2+} constituting the cytosolic Ca^{2+} transient is taken up by the SR, some Ca^{2+} is extruded from the cell by the $\text{Na}^+/\text{Ca}^{2+}$ exchanger (NCX) to balance that which entered via the Ca^{2+} channels in the plasmalemma. Of note, Ca^{2+} release channels do not remain completely

quiescent in diastole but instead mediate a measurable SR Ca^{2+} leak that increases as a function of $[\text{Ca}^{2+}]_{\text{SR}}$, and limits the SR Ca^{2+} content (6,7).

Systolic heart failure (HF) is a disease state associated with weakening of myocardial contractility that ultimately results in catastrophic deterioration of ventricular pump function. Although there are many etiologies of HF, reduced amplitude and prolonged duration of the systolic Ca^{2+} transient are characteristic features of myocytes in HF (8–10). In most studies, including those in human myocytes, these HF-associated changes in Ca^{2+} transients are accompanied by a decrease in the SR Ca^{2+} content (11–14). Although it is clear that reduced SR Ca^{2+} content could lead to reduced systolic Ca^{2+} transients and weakened contractility, the specific mechanisms responsible for the reduced SR Ca^{2+} content in HF remain to be defined. In a number of studies, evidence from protein expression and SERCA2 activity measurements using homogenized tissue preparations suggests that SERCA2 function is inhibited in HF (15–17), although not all studies agree (18,19). At the same time, NCX function/expression is often up-regulated during HF (12,13,20). Both of these changes are expected to result in underfilled SR Ca^{2+} stores by facilitating Ca^{2+} removal from the myocyte at the expense of its uptake into the SR. Additionally, decreased SERCA2 activity could contribute to the slowed decay kinetics of the Ca^{2+} transient in HF, potentially affecting diastolic function. An increase in the SR

Submitted June 7, 2007, and accepted for publication August 24, 2007.

Andriy Belevych, Zuzana Kubalova, and Dmitry Terentyev contributed equally to this work.

Address reprint requests to Sandor Györke, Davis Heart and Lung Research Institute, The Ohio State University Medical Center, 473 W. 12th Avenue, Columbus, OH 43210. E-Mail: Sandor.Gyorke@osumc.edu.

Editor: David A. Eisner.

© 2007 by the Biophysical Society
0006-3495/07/12/4083/10 \$2.00

doi: 10.1529/biophysj.107.114546

Ca^{2+} leak could also contribute to the reduced SR Ca^{2+} content and abnormal Ca^{2+} transients in HF. Although there is considerable disagreement regarding the specific mechanisms governing SR Ca^{2+} leak during HF (21–23), mounting evidence suggests that the RyR2s become functionally hyperactive, rendering the SR membrane much leakier for Ca^{2+} compared with controls (24,25). Strikingly, mutations in RyR2 (or its auxiliary proteins) that result in increased SR Ca^{2+} leak are commonly associated with catecholaminergic polymorphic ventricular tachycardia rather than HF (26,27). Therefore, the specific role of the increased SR Ca^{2+} leak in abnormal Ca^{2+} handling, and in particular to the reduction of $[\text{Ca}^{2+}]_{\text{SR}}$ in HF, has yet to be experimentally defined.

Using a canine chronic model of HF, we recently showed that the RyR2 channel becomes excessively active, resulting in leaky SR Ca^{2+} stores in HF (25). The increase in RyR2 activity is caused by defective modulation of the channel by intra-SR luminal Ca^{2+} , a mechanism that normally operates to terminate SR Ca^{2+} release and keep the RyR2 channels closed (i.e., refractory) during diastole. The goal of this study was to determine the contribution of elevated SR Ca^{2+} leak in HF-related alterations in Ca^{2+} handling relative to the contributions of potential changes in SERCA2 and NCX activities. To this end, we examined intracellular Ca^{2+} cycling by monitoring Ca^{2+} changes in both the extra- and intra-SR compartments in intact and permeabilized myocytes from normal and failing hearts as well as in normal cells exposed to various concentrations of the RyR2 agonist caffeine. Our studies show that enhanced SR Ca^{2+} leak via RyR2s is a primary factor in abnormal intracellular Ca^{2+} handling during heart failure and a critical mediator of reduced SR Ca^{2+} content in failing cardiomyocytes.

MATERIALS AND METHODS

All animal procedures were approved by The Ohio State University Institutional Animal Care and Use Committee. Mongrel dogs had HF induced by RV tachypacing for ≥ 4.5 months, using a previously described protocol (28). Cardiac structure and function of control and HF dogs were analyzed using electrocardiography and echocardiography. Left ventricular fractional shortening was $41.0 \pm 1.6\%$ for 8 control dogs and $14.3 \pm 1.0\%$ for 11 HF dogs. Myocytes were isolated using previously described techniques (25) from the midmyocardium of the left ventricular lateral free wall.

Whole-cell patch clamp recordings of transmembrane ionic currents were performed with an Axopatch 200B amplifier (Axon Instruments, MDS, Sunnyvale, CA). The external solution contained (in mM): 140 NaCl, 5.4 CsCl, 2.0 CaCl_2 , 0.5 MgCl_2 , 10 Hepes, and 5.6 glucose (pH 7.4). Patch pipettes were filled with a solution that contained (in mM): 123.4 CsCl, 20 TEACl, 5 MgATP, 5 NaCl, 1 MgCl_2 , 0.1 Tris GTP, 10 Hepes, and 0.1 Rhod-2 or Fluo-3 K-salt (pH 7.2). Electrical field stimulation experiments were performed using the following external solution (in mM): 140 NaCl, 5.4 KCl, 5.0 CaCl_2 , 0.5 MgCl_2 , 10 Hepes, and 5.6 glucose (pH 7.4).

Intracellular Ca^{2+} imaging was performed using Olympus Fluoview 1000 confocal microscope in line-scan or XY mode. To monitor the intra-SR Ca^{2+} levels, myocytes were loaded with 10 μM Fluo-5N AM for 3–6 h at 37°C. Cytosolic Ca^{2+} measurements were performed using either Rhod-2 or Fluo-3 Ca^{2+} indicators. When measured simultaneously, Fluo-5N and Rhod-2 were excited by 488- and 543-nm laser lines, and fluorescence was

acquired at wavelengths of 500–530 and >590 nm, respectively. Fluo-3 was excited by the 488-nm line of an argon-ion laser, and the fluorescence was acquired at wavelengths >510 nm. To avoid movement artifacts, contraction was suppressed by either 40 μM cytochalasin D (for the experiments shown in Fig. 1) or 10 mM 2,3-butanedione monoxime (BDM) for the experiments shown in Fig. 6.

Intra-SR Ca^{2+} dynamics in Fluo-5N-loaded saponin-permeabilized myocytes were studied using an intracellular solution that contained (mM): 120 potassium aspartate, 20 KCl, 3 MgATP, 10 phosphocreatine, 5 U ml^{-1} creatine phosphokinase, 0.5 EGTA (pCa 7), and 20 HEPES (pH 7.2).

For quantitative studies, the temporal dynamics in fluorescence was expressed as $\Delta F_{\text{CAFF}}/\Delta F_{\text{MAX}} = (F - F_{\text{CAFF}})/(F_{\text{MAX}} - F_{\text{CAFF}})$, where F represents fluorescence at time t , F_{CAFF} represents the fluorescence level of the cells after the application of 10 mM caffeine, and F_{MAX} represents Fluo-5N fluorescence in the presence of 10 mM $[\text{Ca}^{2+}]$. In permeabilized myocytes F_{MAX} was determined by application of 10 mM $[\text{Ca}^{2+}]$ in the presence of 10 mM BDM and 1 μM ionomycin. In intact cells, F_{MAX} was measured by application of 10 mM $[\text{Ca}^{2+}]$ in the presence of 10 mM BDM, 1 μM ionomycin, and 0.1% saponin. The amplitude of SR Ca^{2+} depletion during electrical field stimulation was expressed as $\Delta F/\Delta F_{\text{MAX}} = -(F - F_0)/(F_{\text{MAX}} - F_{\text{CAFF}})$, where F represents nadir fluorescence and F_0 stands for baseline fluorescence. We previously determined that Fluo-5N fluorescence in the presence of 100 μM Ca^{2+} was quenched by $<10\%$ by 10 mM caffeine (29). Therefore, in this study Fluo-5N fluorescence was not corrected for caffeine quenching.

Results are mean \pm SE, with n representing the number of different cells used. Statistical significance was evaluated either by Student's t -test or by ANOVA and t -test with Bonferroni correction, respectively. A value of $p < 0.05$ was considered significant.

RESULTS

Cytosolic and intra-SR $[\text{Ca}^{2+}]$

We monitored intracellular Ca^{2+} cycling in intact control and HF myocytes by simultaneous imaging of $[\text{Ca}^{2+}]$ changes in the cytosolic and SR compartments using the Ca^{2+} indicators Rhod-2 and Fluo-5N, respectively. Representative recordings of cytosolic and intra-SR $[\text{Ca}^{2+}]$ changes in control and HF myocytes during field stimulation at 0.5 Hz are shown in panel A of Fig. 1, whereas panels B–D show averaged data on the amplitude characteristics of the cytosolic and luminal Ca^{2+} signals. Electrical stimulation elicited cytosolic Ca^{2+} transients associated with reciprocal dips in $[\text{Ca}^{2+}]_{\text{SR}}$. The peak amplitude of cytosolic Ca^{2+} transients was significantly reduced in HF myocytes compared with controls (Fig. 1 B), consistent with previous studies (13,15,25,30). At the same time, our $[\text{Ca}^{2+}]_{\text{SR}}$ measurements demonstrated, for the first time, that both the baseline (i.e., diastolic) $[\text{Ca}^{2+}]_{\text{SR}}$ and the extent of luminal $[\text{Ca}^{2+}]$ depletion during systolic Ca^{2+} release are dramatically reduced in HF myocytes (Fig. 1, C and D). These results are consistent with, and significantly extend, previous studies reporting changes in the total SR Ca^{2+} content as assessed by caffeine-induced Ca^{2+} release in HF (11–14).

To learn more about the state of SR Ca^{2+} uptake/retention capacity in HF versus control myocytes, we examined the kinetics of both cytosolic and intra-SR Ca^{2+} transients. The time course of decline of the cytosolic Ca^{2+} transients was characteristically slowed in HF myocytes with respect to




FIGURE 1 Simultaneous measurements of cytosolic and intra-SR $[\text{Ca}^{2+}]$ transients. (A) Representative line-scan images of Rhod-2 (upper) and Fluo-5N (lower) fluorescence in control (C) and heart failure (HF) myocytes. Ca^{2+} transients were evoked by 0.5-Hz electrical field stimulation. (B) Average amplitudes (F/F_0) of cytosolic Ca^{2+} transients were 2.21 ± 0.12 in control (C) and 1.44 ± 0.06 in HF myocytes. (C) Average amplitudes ($\Delta F/\Delta F_{\text{MAX}}$) of SR Ca^{2+} depletion were 0.14 ± 0.04 in control (C) and 0.04 ± 0.007 in HF myocytes. (D) The average levels of free diastolic SR Ca^{2+} ($\Delta F_{\text{CAF}}/\Delta F_{\text{MAX}}$) in control (C) and HF myocytes were 0.53 ± 0.07 and 0.39 ± 0.02 , respectively (* $p < 0.05$; ** $p < 0.01$ versus controls).

controls (Fig. 2, A and B). On average, the rate of Ca^{2+} transient decay was slowed by 36% in HF myocytes (Table 1). In addition to a reduction in Ca^{2+} sequestration, this alteration could be attributable to potential changes in Ca^{2+} transport across the sarcolemma such as slowed Ca^{2+} extrusion or increased Ca^{2+} entry on either the forward- or reverse-mode NCX, respectively. The time course of the $[\text{Ca}^{2+}]_{\text{SR}}$ signal after SR Ca^{2+} release provides a more immediate measure of SR Ca^{2+} resequestration than the decay of the cytosolic Ca^{2+} transient. As demonstrated in Fig. 2 (A, lower panel, and C), the rate of $[\text{Ca}^{2+}]_{\text{SR}}$ recovery after release was slower by 32% in HF myocytes than in controls ($p < 0.05$) (see also Table 1). These results suggest that the ability of SR to resequester (i.e., take up and retain) Ca^{2+} is impaired in HF myocytes.

NCX activity

We obtained an estimate of intrinsic NCX-mediated Ca^{2+} extrusion activity in control versus HF myocytes by measuring the rate of cytosolic Ca^{2+} decline during Ca^{2+} transients induced by caffeine. Fig. 3 provides representative traces of Ca^{2+} transients elicited by 10 mM caffeine (panel A) and pooled data for the amplitude and decay time constants of caffeine-induced Ca^{2+} transients in control and HF myocytes (panels B and C, respectively). The amplitude of the caffeine-induced Ca^{2+} transients was reduced, consistent with the measurements of $[\text{Ca}^{2+}]_{\text{SR}}$ above. The rate of decay of caffeine-induced Ca^{2+} transients showed 31% acceleration in HF

myocytes, suggesting an increase in NCX Ca^{2+} extrusion activity (Table 1). Enhanced Ca^{2+} extrusion via NCX could, to some extent, contribute to the reduced $[\text{Ca}^{2+}]_{\text{SR}}$ in HF myocytes. However, this influence is likely to be minor considering that the rate of Ca^{2+} extrusion via NCX is severalfold slower than the rate of Ca^{2+} resequestration into SR (Table 1).

SERCA2-mediated Ca^{2+} uptake

The ability of the SR to take up and retain Ca^{2+} is determined by two competing processes: SERCA2-mediated transport of Ca^{2+} to the SR lumen and Ca^{2+} leak through RyR2s. To assess the relative roles of these mechanisms in the HF-related decrease of SR net Ca^{2+} sequestration capacity, we performed direct measurements of SERCA2-mediated Ca^{2+} uptake in saponin-permeabilized myocytes in the presence the RyR2 antagonist ruthenium red (Rut Red). In these experiments, the SR was first depleted in a Ca^{2+} -free solution using caffeine (10 mM). Then SR Ca^{2+} uptake was initiated by addition of either 100 or 500 nM Ca^{2+} to the bathing solution and tracked by measuring the elevation of $[\text{Ca}^{2+}]_{\text{SR}}$ with Fluo-5N. Representative traces of SR Ca^{2+} uptake along with the experimental protocol are shown in Fig. 4 A, whereas Fig. 4 B presents pooled data on the time constants of SR Ca^{2+} uptake in control and HF myocytes. In HF myocytes, the time constants of SR Ca^{2+} uptake were not significantly different ($p > 0.5$) from those measured in control myocytes. Thus, the intrinsic Ca^{2+} uptake activity of SERCA2 appears to be unchanged in HF myocytes.




FIGURE 2 HF slows the kinetics of cytosolic and SR Ca^{2+} transients. (A) Representative time-dependent profiles of cytosolic (upper panel) and intra-SR (lower panel) Ca^{2+} transients induced by 0.5-Hz electrical field stimulation in control (C) and HF myocytes. The decay of the transients was fit by a single exponential function with specified time constants. Insets show Ca^{2+} transients with normalized amplitudes. (B) Average time constants of cytosolic Ca^{2+} transient decays were 295 ± 24 ms in control (C) and 447 ± 32 ms in HF myocytes. (C) Average time constants of the SR Ca^{2+} transient decays were 307 ± 26 ms in control (C) and 441 ± 26 ms in HF myocytes (* $p < 0.05$; ** $p < 0.01$).

SR Ca^{2+} leak

We directly measured the rate of SR Ca^{2+} leak by monitoring the time-dependent decline of $[Ca^{2+}]_{\text{SR}}$ in permeabilized myocytes, after inhibition of SERCA2 by thapsigargin (Fig. 5 A). At steady state, $[Ca^{2+}]_{\text{SR}}$ is determined by the balance between SERCA2-mediated Ca^{2+} uptake and Ca^{2+} leak through RyR2s. Similar to the results in intact cells (Fig. 1 D), the baseline $[Ca^{2+}]_{\text{SR}}$ was dramatically lowered in permeabilized myocytes in the HF group compared with controls. Inhibition of SERCA2 resulted in a decline of

TABLE 1 Rate constants of Ca^{2+} transients in control (C) and heart failure (HF) myocytes

Rates	Control	n	Heart failure	n	HF/C
Rate twitch, s^{-1}	3.6 ± 0.3	11	2.3 ± 0.2	10	64%
Rate NCX, s^{-1}	0.39 ± 0.03	9	0.51 ± 0.04	9	131%
Rate SR*, s^{-1}	3.4 ± 0.3	7	2.3 ± 0.1	8	68%

*Defined from the kinetics of $[Ca^{2+}]_{\text{SR}}$ depletion signal; n = number of cells studied.




FIGURE 3 HF reduces SR Ca^{2+} content and moderately increases the rate of cytosolic Ca^{2+} removal by NCX. (A) Representative recordings of Ca^{2+} transients induced by rapid application of 10 mM caffeine in control (C) and HF myocytes. The inset shows caffeine-induced Ca^{2+} transients with normalized amplitudes. (B) Average amplitudes (F/F_0) of caffeine-induced Ca^{2+} transients were 6.14 ± 0.47 in control and 4.69 ± 0.30 in HF myocytes, respectively. (C) The decay time constants of the caffeine-induced Ca^{2+} transients in control and HF myocytes were 2.8 ± 0.3 and 2.0 ± 0.1 s, respectively (* $p < 0.05$).

$[Ca^{2+}]_{\text{SR}}$ in both control and HF myocytes with slopes proportional to Ca^{2+} leak rates. Consistent with a predominant role of Ca^{2+} leak in HF-related reduction of $[Ca^{2+}]_{\text{SR}}$, the SR Ca^{2+} leak rate was markedly enhanced in HF myocytes compared with controls (Fig. 5, A and B, and see Fig. 7 B). To ensure that the increased Ca^{2+} leak observed in HF myocytes was not caused by nonlinear properties of Fluo-5N, the kinetics of $[Ca^{2+}]_{\text{SR}}$ decline in the presence of thapsigargin was analyzed over the same range of Fluo-5N signal in both control and HF myocytes (Fig. 5 B).

To further assess the role of enhanced RyR2-mediated Ca^{2+} leak in HF-related $[Ca^{2+}]_{\text{SR}}$ reduction, we investigated the relative effects of Rut Red on $[Ca^{2+}]_{\text{SR}}$ in permeabilized control and HF myocytes (Fig. 5 C). Application of 10 μ M Rut Red produced a modest increase in $[Ca^{2+}]_{\text{SR}}$ in control myocytes, indicative of a basal SR Ca^{2+} leak occurring via RYR2s. In HF myocytes the effect of Rut Red on $[Ca^{2+}]_{\text{SR}}$ was substantially greater, suggesting that RyR2-mediated SR Ca^{2+} leak plays a significant role in mediating the decrease in $[Ca^{2+}]_{\text{SR}}$ in HF. However, it is to be noted that Rut Red did not raise $[Ca^{2+}]_{\text{SR}}$ completely to the level of $[Ca^{2+}]_{\text{SR}}$ seen in control myocytes (Fig. 5, C and D). This could indicate either a lower efficacy of Rut Red as a RyR2 inhibitor in HF myocytes exhibiting a greater RyR2-mediated SR




FIGURE 4 SERCA2-mediated SR Ca^{2+} uptake is not significantly altered in HF myocytes. (A) Time course of SR Ca^{2+} uptake in control and HF permeabilized myocytes, measured with Fluo-5N-loaded SR, in the presence of 10 μM ruthenium red (Rut Red). The SR $[\text{Ca}^{2+}]$ was depleted with 10 mM caffeine in Ca^{2+} -free solution, and SR Ca^{2+} uptake was initiated by the addition of either 100 or 500 nM of Ca^{2+} . (B) Average time constants (from exponential fit) of SR Ca^{2+} uptake were 45.5 ± 3.1 s in control (C) and 48.9 ± 2.4 s in HF myocytes, when measured in the presence of 100 nM Ca^{2+} , and 12.0 ± 0.7 s in control and 10.5 ± 0.6 s in HF myocytes, when measured in the presence of 500 nM Ca^{2+} .

Ca^{2+} leak or the existence of a Ca^{2+} leak component mediated by a pathway(s) other than the RyR2s such as inositol trisphosphate receptors (IP_3Rs) the expression of which is increased in HF (31).

Comparison with the effects of caffeine

To further examine whether, and to what extent, HF-related changes in Ca^{2+} cycling could be attributed to a Ca^{2+} leak via RyR2s, we investigated changes in cellular Ca^{2+} cycling caused by the RyR2 agonist caffeine in normal myocytes. Fig. 6 shows representative traces of cytosolic and SR luminal Ca^{2+} concentrations in a voltage-clamped myocyte stimulated at 0.5 Hz before and after exposure to two different concentrations of caffeine (3 and 6 mM). Caffeine decreased the amplitude and prolonged the duration of Ca^{2+} transients. At the same time, caffeine led to a decrease in both basal and systolic $[\text{Ca}^{2+}]_{\text{SR}}$. These effects of caffeine were concentration dependent with higher caffeine doses causing more profound changes. The HF-related changes in cytosolic and luminal Ca^{2+} signals could be approximately emulated by 3 mM caffeine. Similar results were obtained in four other myocytes.

The application of caffeine reproduced the leaky SR phenotype in permeabilized control myocytes. As shown in

Fig. 7, A and C, application of low doses of caffeine to a normal myocyte induced a reduction in $[\text{Ca}^{2+}]_{\text{SR}}$ similar to that observed in HF myocytes, and the application of thapsigargin produced a Ca^{2+} leak with a rate comparable, albeit somewhat faster than, that in HF myocytes. Pooled data on the rate of SR Ca^{2+} leak recorded in the presence of 1 mM caffeine in comparison with basal leak rates measured in control and HF myocytes are presented in Fig. 7 B. The effects of two incremental additions of caffeine (0.5 and 2 mM) on basal $[\text{Ca}^{2+}]_{\text{SR}}$ are documented in Fig. 7 C. Again, application of 0.5 mM of caffeine lowered $[\text{Ca}^{2+}]_{\text{SR}}$ to a level corresponding to that in HF, and the higher dose induced a larger although still incomplete depletion of $[\text{Ca}^{2+}]_{\text{SR}}$ as revealed by addition of 10 mM at the end of the experiment. Importantly, Rut Red added in the presence of 1 mM caffeine failed to elevate $[\text{Ca}^{2+}]_{\text{SR}}$ to the level attained with the same dose of Rut Red in the absence of caffeine (Fig. 7, C and D). Reminiscent of the experiments in HF myocytes, these results suggest that inhibition of RyR2s by Rut Red is incomplete at the concentration used (10 μM) or that the inhibition can be overcome by caffeine. Collectively, these results suggest that the HF-related changes in cellular Ca^{2+} handling can be reproduced reasonably well in control myocytes with caffeine at concentrations of 0.5–3 mM, depending on experimental settings.

DISCUSSION

In this study, we investigated the role of elevated SR Ca^{2+} leak through RyR2s in HF-related abnormalities of intracellular Ca^{2+} handling, using a canine model of chronic HF. Our study shows for the first time that the increase in the RyR2-mediated Ca^{2+} leak is a major factor in the reduced SR Ca^{2+} content and the decreased amplitude and slowed time course of cytosolic Ca^{2+} transients in cardiac myocytes from failing hearts.

Role of enhanced SR Ca^{2+} leak in abnormal Ca^{2+} handling in HF

Consistent with previous studies (13,15,25,30), the cytosolic Ca^{2+} transients were markedly reduced in amplitude and slowed in duration in HF myocytes compared with control myocytes, changes paralleled by a significant reduction in the total SR Ca^{2+} content. These alterations in Ca^{2+} handling are considered to be hallmarks of HF (8–10). The HF-induced reduction of the size of the functional Ca^{2+} store could be caused either by a potential decrease in SR volume (per-myocyte volume) or by a reduction of $[\text{Ca}^{2+}]$ in the lumen of SR in HF myocytes (32). Our direct measurements of $[\text{Ca}^{2+}]_{\text{SR}}$ in both intact and permeabilized cardiac cells demonstrated that SR luminal $[\text{Ca}^{2+}]$ is manifestly lowered in HF myocytes, suggesting that alterations in Ca^{2+} transport rather than fractional SR volume contraction accounts for the




FIGURE 5 HF increases SR Ca^{2+} leak. (A) Time-dependent profiles of intra-SR Ca^{2+} signals. Application of 10 μ M of thapsigargin (Tg) evokes a steady loss of intra-SR Ca^{2+} , visualized by the decline of the Fluo-5N signal, which was significantly faster in permeabilized myocytes from failing hearts. Then 10 mM caffeine (Caf) was applied to determine the Fluo-5N signal with depleted SR. Maximal Fluo-5N signal was determined by simultaneous application of 1 μ M ionomycin with 10 mM Ca^{2+} and 10 mM BDM. (B) Time course of normalized Fluo-5N signals in control and HF myocytes measured in the presence of Tg, as demonstrated in panel A. Kinetic analysis was performed in both control and HF over the same range of Fluo-5N signal, as indicated in panel A by the wide black line. Dotted lines represent exponential fit to the data. (C) Time-dependent profiles of intra-SR Fluo-5N signals before and after application of 10 μ M ruthenium red (Rut Red) in control and HF cells. (D) In control myocytes, normalized $[Ca^{2+}]_{SR}$ levels were 0.83 ± 0.02 in the absence of, and 0.92 ± 0.02 in the presence of, Rut Red, respectively. In HF myocytes, normalized $[Ca^{2+}]_{SR}$ levels were 0.61 ± 0.03 in the absence of, and 0.77 ± 0.04 in the presence of, Rut Red, respectively (* $p < 0.05$ versus control; ** $p < 0.01$ versus control).

diminished Ca^{2+} release capacity of SR in HF. Potential contributors to the decreased $[Ca^{2+}]_{SR}$ in HF include reduced SR Ca^{2+} -ATPase function, enhanced NCX Ca^{2+} extrusion activity, and/or increased SR Ca^{2+} leak. Based on our experiments, SR Ca^{2+} uptake rate was not significantly altered in HF myocytes. This lack of functional changes is consistent with the unchanged levels of SERCA2a expressed in failing myocytes using this particular model of HF (25). Although NCX activity was accelerated in HF myocytes, these changes in NCX function were relatively modest ($\sim 30\%$) and could not account for the altered Ca^{2+} transients in HF myocytes. Indeed, we found that HF myocytes exhibited a similar reduction in $[Ca^{2+}]_{SR}$ regardless of whether they were intact or permeabilized (Fig. 1, A and D, and Fig. 5, C and D), suggesting that NCX is not a major contributor to the reduced $[Ca^{2+}]_{SR}$ in HF under our experimental conditions. At the same time, SR Ca^{2+} leak, measured directly as a reduction in $[Ca^{2+}]_{SR}$ after inhibition of SERCA2 by thapsigargin, was markedly enhanced in HF myocytes. Moreover, the reduced $[Ca^{2+}]_{SR}$ in HF myocytes could be nearly completely restored by the RyR2 channel blocker Rut Red. Thus, based on our experiments, enhanced SR Ca^{2+} leak is a critical factor determining the reduced $[Ca^{2+}]_{SR}$ in HF with altered SERCA2- and NCX-mediated Ca^{2+} transport playing no major role in modulating $[Ca^{2+}]_{SR}$.

Importantly, the increased SR Ca^{2+} leak not only contributed to the reduced SR Ca^{2+} content but also influenced the dynamics of resequestration of Ca^{2+} into the SR and was also likely to be responsible for the slowed kinetics of the cytosolic Ca^{2+} transients in HF myocytes. Indeed, the kinetics of recovery of both $[Ca^{2+}]_{SR}$ and cytosolic Ca^{2+} signals after each release was slowed in HF myocytes despite the fact that SERCA2 and NCX activities exhibited either no change or were increased, respectively, in HF myocytes. Our findings are consistent with those of Litwin et al. (33), which showed that sustained SR Ca^{2+} release rather than inhibition of SR Ca^{2+} uptake accounts for the slowed kinetics of the cytosolic Ca^{2+} transients in myocytes from infarcted rabbits. These results along with those obtained with caffeine (see below) suggest that caution must be exercised when using kinetics of Ca^{2+} transient decay as a measure of SERCA2 Ca^{2+} transport activity, especially in disease states where SR Ca^{2+} leak can profoundly affect the Ca^{2+} transient time course.

Effects of caffeine

The effects of HF on cytosolic and SR luminal Ca^{2+} signals could be reasonably well mimicked by the RyR2 channel agonist caffeine, further supporting the notion that Ca^{2+} leak via RyR2s is a major contributor to the HF-related changes in




FIGURE 6 Caffeine mimics the properties of global Ca^{2+} release observed in HF. Representative simultaneous recordings of cytosolic (measured with Rhod-2) and intra-SR $[\text{Ca}^{2+}]$ (measured with Fluo-5N) signals in voltage-clamped myocytes before and after application of the specified concentrations of caffeine. Caffeine produced significant deceleration of relaxation and decreased amplitudes of the cytosolic and intra-SR $[\text{Ca}^{2+}]$ transients. Ca^{2+} transients were evoked by 300-ms depolarizing steps from a holding potential of -50 mV to 0 mV every 2 s.

myocyte Ca^{2+} handling. Similar to the HF phenotype, caffeine at intermediate to high concentrations reduced the amplitude and slowed the time course of cytosolic Ca^{2+} transients and increased baseline (diastolic) $[\text{Ca}^{2+}]_{\text{cyt}}$ in control cells. The inhibitory effects of intermediate and high concentrations of caffeine on the amplitude and rate of decay of the cytosolic Ca^{2+} transient are consistent with previous studies (34). Caffeine also reduced both the diastolic and systolic $[\text{Ca}^{2+}]_{\text{SR}}$ and slowed the recovery rate of $[\text{Ca}^{2+}]_{\text{SR}}$ after Ca^{2+} release. The HF-induced changes in the parameters of cytosolic and luminal Ca^{2+} signals could be approximately matched with the addition of 0.5 – 3 mM caffeine, permitting us to “calibrate” the impact of HF on SR Ca^{2+} leak in terms of effects of a well-studied RyR opener.


Considerations of Ca^{2+} homeostasis

Based on studies using low concentrations of the RyR2 channel modulators caffeine and tetracaine, it has been shown (35) that the SR Ca^{2+} release mechanism in cardiac

myocytes possesses a capacity for self-regulation, which allows myocytes to maintain Ca^{2+} transients of constant amplitude in the face of interventions that alter RyR2 activity. Thus, a reduction in Ca^{2+} transient amplitude by such an intervention would result in both reduced Ca^{2+} extrusion via NCX and reduced Ca^{2+} -dependent inactivation of I_{Ca} and, hence, increased retention of Ca^{2+} in the myocyte, which would contribute to the Ca^{2+} transient during the next Ca^{2+} release cycle. Therefore, one might expect that the RyR2-mediated leak in HF would lead only to a transient change in the amplitude of cytosolic Ca^{2+} transients without producing steady-state inhibitory (or potentiatory) effects on cytosolic Ca^{2+} transients. However, as we demonstrated by the application of moderate to high doses of caffeine, the ability of the SR to preserve normal Ca^{2+} release amplitude depends on the extent to which the RyR2 function is altered. When the RyR2 becomes excessively active, the SR loses its capacity to retain Ca^{2+} during diastole, resulting in a partial or even complete elimination of the SR Ca^{2+} store. Because the majority of Ca^{2+} contributing to the Ca^{2+} transient comes from the SR, this unavoidably leads to reduced Ca^{2+} transients as is manifested in HF myocytes.

Mechanisms for enhanced RyR2 activity

The specific biochemical defect(s) causing RyR2 to become leaky in HF is not known. It has been proposed that RyR2 phosphorylation either by PKA or CAMKII may contribute to the SR leak in HF by rendering RyR2s hyperactive (21,36–39). Alternatively, enhanced RyR2 activity could be caused by modification of the channel protein by reactive oxygen or reactive nitrogen species generated in HF (40,41). Recently, using the same canine model, we demonstrated that the enhanced RyR2 activity in HF is caused by sensitization of the RyR2 to activation by luminal Ca^{2+} (25). This finding explains why SR Ca^{2+} leak is high despite the reduced SR luminal Ca^{2+} levels in HF myocytes, considering the well-known positive relationship between SR Ca^{2+} load and RyR2 activity (42). Consistent with this mechanism, our direct measurements of $[\text{Ca}^{2+}]_{\text{SR}}$ showed that Ca^{2+} release terminates at much lower $[\text{Ca}^{2+}]_{\text{SR}}$ in HF myocytes compared with normal myocytes, indicative of an extended range of Ca^{2+} concentrations enhancing RyR2 channel activity in HF. It remains to be seen whether these changes in RyR2 function are also modulated by changes in RyR2 phosphorylation or redox modulation. Because regulation of RyR2s by luminal Ca^{2+} may involve RyR2’s luminal binding partners, including calsequestrin, triadin, and junctin (43,44), it is also conceivable that alterations in interactions of RyR2 with these proteins contribute to abnormal RyR2 channel function in HF. Although the levels of these proteins are not changed, RyR2 expression is markedly reduced in this model of HF (25). Because both triadin and junctin appear to increase RyR2 activity (44), an increased ratio of triadin and junctin to RyR2 could contribute



Ca^{2+} and 10 mM BDM. In the absence of caffeine, normalized $[Ca^{2+}]_{SR}$ levels were 0.73 ± 0.03 before and 0.92 ± 0.03 during application of Rut Red, respectively. In the presence of 2 mM caffeine, normalized $[Ca^{2+}]_{SR}$ levels were 0.28 ± 0.03 before and 0.76 ± 0.03 during the application of Rut Red, respectively (* $p < 0.05$ versus control; ** $p < 0.01$ versus control).

to increased RyR2 function in HF. Additionally, CASQ2 glycosylation is dramatically altered in HF, indicative of defective junctional SR trafficking and Ca^{2+} release complex assembly (45).

Comparison with previous studies

Our results corroborate previous studies that demonstrated that an elevated SR Ca^{2+} leak exists in myocytes from failing hearts using rabbit and dog HF models (24,25). Moreover, our data show that enhanced SR Ca^{2+} leak can be a primary determinant of altered Ca^{2+} handling in HF myocytes. At this time it is unclear whether the prevailing role of SR Ca^{2+} leak and the apparent lack of effects on SR Ca^{2+} uptake are specific features of this particular disease model or are more general properties of HF. The contribution of SR Ca^{2+} leak to HF-related alterations in SR function may vary among different models and stages of HF and is difficult to quantify because of the presence of competing Ca^{2+} fluxes, including those mediated by SERCA2 and NCX. Application of approaches developed in this study to other models and stages of HF should certainly clarify this issue.

Using a shorter-term (3–6 weeks) canine model of tachypacing-induced HF, Hobai and O'Rourke (13) showed that reduced SR Ca^{2+} content is responsible for depressed SR Ca^{2+} release in HF. Although potential changes in SERCA2 function and SR Ca^{2+} leak were not estimated in that study, the marked prolongation of the Ca^{2+} transient decay indicates that either the uptake or retention of Ca^{2+} by the SR, or both, were affected through potential inhibition of SERCA2 and/or stimulation of SR Ca^{2+} leak. At the same time, NCX Ca^{2+} extrusion activity was enhanced by 50% and was also likely to be contributing to the reduced SR

Ca^{2+} content. A study using a rabbit model of HF found a substantial SR Ca^{2+} leak (24), but its significance was deemed secondary to enhanced NCX-mediated Ca^{2+} extrusion in view of the marked up-regulation of NCX activity in this model. In human HF, NCX was shown to change little, and alterations in Ca^{2+} handling were ascribed to the reduced Ca^{2+} uptake capacity of the SR, manifested as slowed Ca^{2+} transient decay (14). Because the slowed kinetics of the Ca^{2+} transient could be attributable to both slowed SERCA2-mediated Ca^{2+} uptake and increased SR Ca^{2+} leak, it is possible that in human HF, increased SR Ca^{2+} leak is an important factor in acquisition of the HF-related Ca^{2+} transient phenotype, as we show in our chronic canine model of HF. Although it demonstrates the importance of a SR Ca^{2+} leak, our study does not rule out other potential mechanisms, including failure of SR Ca^{2+} release activation caused by structural changes (46) or alterations in myocyte electrical excitability (47), contributing to defective Ca^{2+} signaling in the failing heart.

CONCLUSION

In conclusion, this study used a large animal model of chronic heart failure, closely relevant to human disease, to demonstrate that elevated Ca^{2+} leak from the SR via RyR2s can be a major factor in determining the altered properties of cytosolic Ca^{2+} transients in HF. Our findings support the notion that targeting the RyR2 might be a logical therapeutic approach to treating HF (48). However, implementing a successful therapy based on RyR2 targeting could be challenging, considering the complex nature of store-mediated Ca^{2+} signaling. Indeed, inhibition of RyR2s may fix the leak but at the same time impair systolic function. Establishing

the precise molecular mechanism(s) responsible for HF-related abnormalities in RyR2s should facilitate the development of a rational strategy to normalize Ca^{2+} cycling and myocardial performance in HF.

Authors thank Arun Sridhar for his help in myocyte isolation.

This work was supported by the American Heart Association (A.B., D.T., C.A.C.), National Institutes of Health Grants HL074045 and HL063043 (S.G.), and by the Slovak Research and Development Agency under contract No. LPP-0099-06. Pacemakers were generously provided by Medtronic, Inc., Minneapolis, MN.

REFERENCES

- Bers, D. M. 2001. Excitation-contraction coupling and cardiac contractile force. Dordrecht, Boston: Kluwer Academic Publishers. xxiv.
- Fabiato, A. 1985. Time and calcium dependence of activation and inactivation of calcium-induced release of calcium from the sarcoplasmic reticulum of a skinned canine cardiac Purkinje cell. *J. Gen. Physiol.* 85:247–289.
- Terentyev, D., S. Viatchenko-Karpinski, H. H. Valdivia, A. L. Escobar, and S. Gyorke. 2002. Luminal Ca^{2+} controls termination and refractory behavior of Ca^{2+} -induced Ca^{2+} release in cardiac myocytes. *Circ. Res.* 91:414–420.
- Shannon, T. R., T. Guo, and D. M. Bers. 2003. Ca^{2+} scraps: local depletions of free $[\text{Ca}^{2+}]$ in cardiac sarcoplasmic reticulum during contractions leave substantial Ca^{2+} reserve. *Circ. Res.* 93:40–45.
- Sobie, E. A., K. W. Dilly, J. dos Santos Cruz, W. J. Lederer, and M. S. Jafri. 2002. Termination of cardiac Ca^{2+} sparks: an investigative mathematical model of calcium-induced calcium release. *Biophys. J.* 83:59–78.
- Lukyanenko, V., S. Viatchenko-Karpinski, A. Smirnov, T. F. Wiesner, and S. Gyorke. 2001. Dynamic regulation of sarcoplasmic reticulum Ca^{2+} content and release by luminal Ca^{2+} -sensitive leak in rat ventricular myocytes. *Biophys. J.* 81:785–798.
- Shannon, T. R., K. S. Ginsburg, and D. M. Bers. 2002. Quantitative assessment of the SR Ca^{2+} leak-load relationship. *Circ. Res.* 91:594–600.
- Hasenfuss, G., and B. Pieske. 2002. Calcium cycling in congestive heart failure. *J. Mol. Cell. Cardiol.* 34:951–969.
- Houser, S. R., and K. B. Margulies. 2003. Is depressed myocyte contractility centrally involved in heart failure? *Circ. Res.* 92:350–358.
- Sipido, K. R., and D. Eisner. 2005. Something old, something new: changing views on the cellular mechanisms of heart failure. *Cardiovasc. Res.* 68:167–174.
- Lindner, M., E. Erdmann, and D. J. Beuckelmann. 1998. Calcium content of the sarcoplasmic reticulum in isolated ventricular myocytes from patients with terminal heart failure. *J. Mol. Cell. Cardiol.* 30:743–749.
- Pogwizd, S. M., M. Qi, W. Yuan, A. M. Samarel, and D. M. Bers. 1999. Upregulation of $\text{Na}^+/\text{Ca}^{2+}$ exchanger expression and function in an arrhythmogenic rabbit model of heart failure. *Circ. Res.* 85:1009–1019.
- Hobai, I. A., and B. O'Rourke. 2001. Decreased sarcoplasmic reticulum calcium content is responsible for defective excitation-contraction coupling in canine heart failure. *Circulation.* 103:1577–1584.
- Piacentino, V., 3rd, C. R. Weber, X. Chen, J. Weissner-Thomas, K. B. Margulies, D. M. Bers, and S. R. Houser. 2003. Cellular basis of abnormal calcium transients of failing human ventricular myocytes. *Circ. Res.* 92:651–658.
- Pieske, B., B. Kretschmann, M. Meyer, C. Holubarsch, J. Weirich, H. Posival, K. Minami, H. Just, and G. Hasenfuss. 1995. Alterations in intracellular calcium handling associated with the inverse force-frequency relation in human dilated cardiomyopathy. *Circulation.* 92:1169–1178.
- Schmidt, U., R. J. Hajjar, P. A. Helm, C. S. Kim, A. A. Doye, and J. K. Gwathmey. 1998. Contribution of abnormal sarcoplasmic reticulum ATPase activity to systolic and diastolic dysfunction in human heart failure. *J. Mol. Cell. Cardiol.* 30:1929–1937.
- Jiang, M. T., A. J. Lokuta, E. F. Farrell, M. R. Wolff, R. A. Haworth, and H. H. Valdivia. 2002. Abnormal Ca^{2+} release, but normal ryanodine receptors, in canine and human heart failure. *Circ. Res.* 91:1015–1022.
- Movsesian, M. A., M. Karimi, K. Green, and L. R. Jones. 1994. Ca^{2+} -transporting ATPase, phospholamban, and calsequestrin levels in nonfailing and failing human myocardium. *Circulation.* 90:653–657.
- Schwinger, R. H., M. Bohm, U. Schmidt, P. Karczewski, U. Bavendiek, M. Flesch, E. G. Krause, and E. Erdmann. 1995. Unchanged protein levels of SERCA II and phospholamban but reduced Ca^{2+} uptake and Ca^{2+} -ATPase activity of cardiac sarcoplasmic reticulum from dilated cardiomyopathy patients compared with patients with nonfailing hearts. *Circulation.* 92:3220–3228.
- Pieske, B., L. S. Maier, D. M. Bers, and G. Hasenfuss. 1999. Ca^{2+} handling and sarcoplasmic reticulum Ca^{2+} content in isolated failing and nonfailing human myocardium. *Circ. Res.* 85:38–46.
- Marx, S. O., S. Reiken, Y. Hisamatsu, T. Jayaraman, D. Burkoff, N. Rosembly, and A. R. Marks. 2000. PKA phosphorylation dissociates FKBP12.6 from the calcium release channel (ryanodine receptor): defective regulation in failing hearts. *Cell.* 101:365–376.
- Marks, A. R. 2003. A guide for the perplexed: towards an understanding of the molecular basis of heart failure. *Circulation.* 107:1456–1459.
- Bers, D. M., D. A. Eisner, and H. H. Valdivia. 2003. Sarcoplasmic reticulum Ca^{2+} and heart failure: roles of diastolic leak and Ca^{2+} transport. *Circ. Res.* 93:487–490.
- Shannon, T. R., S. M. Pogwizd, and D. M. Bers. 2003. Elevated sarcoplasmic reticulum Ca^{2+} leak in intact ventricular myocytes from rabbits in heart failure. *Circ. Res.* 93:592–594.
- Kubalova, Z., D. Terentyev, S. Viatchenko-Karpinski, Y. Nishijima, I. Gyorke, R. Terentyeva, D. N. da Cunha, A. Sridhar, D. S. Feldman, R. L. Hamlin, C. A. Carnes, and S. Györke. 2005. Abnormal intrastore calcium signaling in chronic heart failure. *Proc. Natl. Acad. Sci. USA.* 102:14104–14109.
- Priori, S. G., C. Napolitano, N. Tiso, M. Memmi, G. Vignati, R. Bloise, V. Sorrentino, and G. A. Danieli. 2001. Mutations in the cardiac ryanodine receptor gene (hRyR2) underlie catecholaminergic polymorphic ventricular tachycardia. *Circulation.* 103:196–200.
- di Barletta, M. R., S. Viatchenko-Karpinski, A. Nori, M. Memmi, D. Terentyev, F. Turcato, G. Valle, N. Rizzi, C. Napolitano, S. Gyorke, P. Volpe, and S. G. Priori. 2006. Clinical phenotype and functional characterization of CASQ2 mutations associated with catecholaminergic polymorphic ventricular tachycardia. *Circulation.* 114:1012–1019.
- Nishijima, Y., D. S. Feldman, J. D. Bonagura, Y. Ozkanlar, P. J. Jenkins, V. A. Lacombe, W. T. Abraham, R. L. Hamlin, and C. A. Carnes. 2005. Canine nonischemic left ventricular dysfunction: a model of chronic human cardiomyopathy. *J. Card. Fail.* 11:638–644.
- Kubalova, Z., I. Gyorke, R. Terentyeva, S. Viatchenko-Karpinski, D. Terentyev, S. C. Williams, and S. Gyorke. 2004. Modulation of cytosolic and intra-sarcoplasmic reticulum calcium waves by calsequestrin in rat cardiac myocytes. *J. Physiol.* 561:515–524.
- Beuckelmann, D. J., M. Nabauer, and E. Erdmann. 1992. Intracellular calcium handling in isolated ventricular myocytes from patients with terminal heart failure. *Circulation.* 85:1046–1055.
- Go, L. O., M. C. Moschella, J. Watras, K. K. Handa, B. S. Fyfe, and A. R. Marks. 1995. Differential regulation of two types of intracellular calcium release channels during end-stage heart failure. *J. Clin. Invest.* 95:888–894.
- Venetucci, L., A. W. Trafford, and D. A. Eisner. 2003. Illuminating sarcoplasmic reticulum calcium. *Circ. Res.* 93:4–5.

33. Litwin, S. E., D. Zhang, and J. H. Bridge. 2000. Dyssynchronous Ca^{2+} sparks in myocytes from infarcted hearts. *Circ. Res.* 87:1040–1047.
34. Negretti, N., S. C. O'Neill, and D. A. Eisner. 1993. The effects of inhibitors of sarcoplasmic reticulum function on the systolic Ca^{2+} transient in rat ventricular myocytes. *J. Physiol.* 468:35–52.
35. Eisner, D. A., A. W. Trafford, M. E. Diaz, C. L. Overend, and S. C. O'Neill. 1998. The control of Ca release from the cardiac sarcoplasmic reticulum: regulation versus autoregulation. *Cardiovasc. Res.* 38: 589–604.
36. Wehrens, X. H., S. E. Lehnart, and A. R. Marks. 2005. Intracellular calcium release and cardiac disease. *Annu. Rev. Physiol.* 67:69–98.
37. Ai, X., J. W. Curran, T. R. Shannon, D. M. Bers, and S. M. Pogwizd. 2005. Ca^{2+} /calmodulin-dependent protein kinase modulates cardiac ryanodine receptor phosphorylation and sarcoplasmic reticulum Ca^{2+} leak in heart failure. *Circ. Res.* 97:1314–1322.
38. Maier, L. S., and D. M. Bers. 2007. Role of Ca^{2+} /calmodulin-dependent protein kinase (CaMK) in excitation-contraction coupling in the heart. *Cardiovasc. Res.* 73:631–640.
39. Litwin, S. E. 2006. "Ryanogate": who leaked the calcium? *Circ. Res.* 98:165–168.
40. Zima, A. V., and L. A. Blatter. 2006. Redox regulation of cardiac calcium channels and transporters. *Cardiovasc. Res.* 71:310–321.
41. Tocchetti, C. G., W. Wang, J. P. Froehlich, S. Huke, M. A. Aon, G. M. Wilson, G. Di Benedetto, B. O'Rourke, W. D. Gao, D. A. Wink, J. P. Toscano, M. Zaccolo, D. M. Bers, H. H. Valdivia, H. Cheng, D. A. Kass, and N. Paolocci. 2007. Nitroxyl improves cellular heart function by directly enhancing cardiac sarcoplasmic reticulum Ca^{2+} cycling. *Circ. Res.* 100:96–104.
42. Gyorke, S., I. Gyorke, V. Lukyanenko, D. Terentyev, S. Viatchenko-Karpinski, and T. F. Wiesner. 2002. Regulation of sarcoplasmic reticulum calcium release by luminal calcium in cardiac muscle. *Front. Biosci.* 7:d1454–d1463.
43. Zhang, L., J. Kelley, G. Schmeisser, Y. M. Kobayashi, and L. R. Jones. 1997. Complex formation between junctin, triadin, calsequestrin, and the ryanodine receptor. Proteins of the cardiac junctional sarcoplasmic reticulum membrane. *J. Biol. Chem.* 272:23389–23397.
44. Gyorke, I., N. Hester, L. R. Jones, and S. Gyorke. 2004. The role of calsequestrin, triadin, and junctin in conferring cardiac ryanodine receptor responsiveness to luminal calcium. *Biophys. J.* 86:2121–2128.
45. Kiarash, A., C. E. Kelly, B. S. Phinney, H. H. Valdivia, J. Abrams, and S. E. Cala. 2004. Defective glycosylation of calsequestrin in heart failure. *Cardiovasc. Res.* 63:264–272.
46. Song, L. S., E. A. Sobie, S. McCulle, W. J. Lederer, C. W. Balke, and H. Cheng. 2006. Orphaned ryanodine receptors in the failing heart. *Proc. Natl. Acad. Sci. USA.* 103:4305–4310.
47. Harris, D. M., G. D. Mills, X. Chen, H. Kubo, R. M. Berretta, V. S. Votaw, L. F. Santana, and S. R. Houser. 2005. Alterations in early action potential repolarization causes localized failure of sarcoplasmic reticulum Ca^{2+} release. *Circ. Res.* 96:543–550.
48. Wehrens, X. H., and A. R. Marks. 2004. Novel therapeutic approaches for heart failure by normalizing calcium cycling. *Nat. Rev. Drug Discov.* 3:565–573.